The US Food and Drug Administration (FDA) has granted Siemens Healthineers 510(k) authorization for the addition of new functionality to its Ethos therapy system. This most recent iteration introduces a more efficient workflow for the daily adaptation of treatment across multiple body areas, thereby improving connectivity to patient data. Ethos 2.0 simplifies the implementation of adaptive, personalized radiotherapy, offering clinical teams a versatile solution to optimize operational and clinical efficiencies. Key improvements include advanced algorithms powering the Ethos Intelligent Optimization Engine, which now integrates images acquired with the HyperSight imaging solution to streamline workflows and enable direct dose calculation to adapt treatments. Furthermore, the system now automatically contours a significantly higher number of AI-segmented anatomical structures, reducing the need for manual contouring.
Ethos 2.0 also enables the seamless exchange and sharing of data with the ARIA CORE oncology management solution, thereby improving the efficacy of patient management. Since its introduction in 2019, the Ethos system has demonstrated its value as an effective radiotherapy tool. Varian data indicates that the adapted treatment plan was selected by providers using Ethos 88% of the time, suggesting its advantages in terms of patient care. Varian, which is now a division of Siemens Healthineers, has been at the forefront of the development and delivery of innovative technologies and solutions for more than 75 years, enabling care providers worldwide to treat millions of patients annually.
